Verge Genomics Senior Director, Head of Drug Discovery, Irene Choi, will present at the 5th Annual ALS Research Symposium on Friday October 7, 2022.
Read MoreVerge Genomics Victor Hanson-Smith, Head of Computational Biology, will present on Machine Learning for Accelerating Target Identification: Costs and Benefits at Augmented Intelligence In Drug Discovery XCHANGE.
Read More…was one of the first companies to uncover PIKfyve, a novel target for amyotrophic lateral sclerosis (ALS), and to develop a treatment candidate in-house. That investigational ALS treatment is expected to begin clinical testing later this year, just four years after the target’s identification.
Read MoreFierce Biotech Names Verge Genomics a 2022 “Fierce 15” Biotech Company
Read More
Verge Genomics Chief Business Officer, Jane Rhodes, PhD, to participate in Fierce Biotech Summit panel: Leverage AI and ML to advance discovery and accelerate drug development.
Read More